NDA 017058 · Hikma
Methadone Hydrochloride
Methadone Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1973
Mar 14, 1973
Approved uses
1
Original approval plus efficacy supplements
Registered trials
340
70 Phase 3, 35 recruiting
FAERS reports
43,046
37,169 serious, 13,745 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LIFE-THREATENING RESPIRATORY DEPRESSION, LIFE-THREATENING QT PROLONGATION, ACCIDENTAL INGESTION, ABUSE POTENTIAL, INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES and TREATMENT FOR OPIOID ADDICTION Life-Threatening Respiratory Depression Respiratory depression, including fatal cases, have been reported during initiation and conversion of patients to methadone, and even when the drug has been used as recommended and not misused or abused [see Warnings and Precautions ( 5.1 )]. Proper dosing and titration are essential and DISKETS Dispersible Tablets should only be prescribed by healthcare professionals who are knowledgeable in the use of methadone for detoxification and maintenance treatment of opioid addiction. Monitor for respiratory depression, especially during initiation of DISKETS Dispersible Tablets or following a dose increase. The peak respiratory depressant...
What it is approved for
From the label in effect Dec 1, 2025.
DISKETS Dispersible Tablets contain methadone, an opioid agonist indicated for the: • Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). • Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. Limitations of Use Methadone products used for the treatment of opioid addiction in detoxification or maintenance programs are subject to the conditions for distribution and use required under 42 CFR 8.12 [see Dosage and Administration ( 2.1 )] . DISKETS Dispersible Tablets are an opioid agonist indicated for the: • Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). ( 1 ) • Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. ( 1 ) Limitations of Use • Methadone products used for the treatment of opioid addiction in detoxification or maintenance programs are subject to the conditions for distribution and use required under 21 CFR, Title 42, Sec 8. ( 1 , 2.1 )
Mechanism: Methadone hydrochloride is a mu-agonist; a synthetic opioid with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The methadone withdrawal syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone’s efficacy is...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 14, 1973 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- METHADONE HYDROCHLORIDE · METHADONE HYDROCHLORIDE 40MG · TABLET, FOR SUSPENSION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Methadone" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Combined Therapy of Methadone and DextromethrophanPivotal-lookingStatus unknown
National Cheng-Kung University HospitalAcademic, hospital or other
NCT01189097 · 1,500 participants (planned) · Start Apr 2008 · Primary completion Mar 2011
Drug: Dextromethorphan; Dextromethorphan · For: Opioid Abuse
Sites: Tainan, Taiwan
- Starting Treatment With Agonist Replacement Therapies (START)Pivotal-lookingCompleted
University of California, Los AngelesAcademic, hospital or other
NCT00315341 · 1,269 participants · Start Apr 2006 · Primary completion Aug 2010
Drug: Buprenorphine/naloxone; Methadone · For: Opiate-related Disorders
Sites: Los Angeles, California; Sacramento, California; San Francisco, California · 9 sites in all
- The German Project of Heroin Assisted Treatment of Opiate Dependent PatientsPivotal-lookingCompleted
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
NCT00268814 · 1,015 participants · Start Mar 2002 · Primary completion Dec 2003
Drug: Diacetylmorphine; Methadone · For: Opioid Dependence
Sites: Karlsruhe, Germany; Munich, Germany; Hamburg, Germany · 7 sites in all
- Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement)Pivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT03726268 · 907 participants · Start Nov 29, 2018 · Primary completion Jul 30, 2023
Drug: Methadone; Fentanyl and 3 more · For: Opioid Use; Pain, Postoperative
Sites: Durham, North Carolina
- Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.Pivotal-lookingRecruiting
Yale UniversityAcademic, hospital or other
NCT06323824 · 600 participants (planned) · Start Jun 4, 2024 · Primary completion Dec 2028
Drug: Methadone; Buprenorphine (BUP) · For: Opioid Use Disorder
Sites: Oakland, California; San Francisco, California; Denver, Colorado · 6 sites in all
- Efficacy Evaluation of Traditional Chinese Medicine JITAI Combined Comprehensive Model Among Heroin Addicts After DetoxificationPivotal-lookingCompleted
Shanghai Mental Health CenterAcademic, hospital or other
NCT01580163 · 554 participants · Start Sep 2009 · Primary completion Aug 2013
Drug: JITAI Combined with psychological intervention; Methadone and 1 more · For: Heroin Addiction
Sites: Beijing, China; Changsha, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug dependence5,670
- toxicity to various agents5,414
- drug abuse4,962
- overdose3,906
- pain3,705
- death3,637
- drug withdrawal syndrome2,390
- emotional distress2,388
- drug ineffective1,791
- foetal exposure during pregnancy1,694
- drug interaction1,684
- nausea1,655
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 85 |
| 2005 | 290 |
| 2006 | 202 |
| 2007 | 83 |
| 2008 | 76 |
| 2009 | 498 |
| 2010 | 833 |
| 2011 | 699 |
| 2012 | 898 |
| 2013 | 1,896 |
| 2014 | 2,163 |
| 2015 | 2,722 |
| 2016 | 2,142 |
| 2017 | 2,404 |
| 2018 | 3,491 |
| 2019 | 2,699 |
| 2020 | 4,483 |
| 2021 | 5,417 |
| 2022 | 3,379 |
| 2023 | 2,750 |
| 2024 | 2,412 |
| 2025 | 2,050 |
| 2026 | 1,373 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.
Degenhardt L, Clark B, Macpherson G, et al. · Lancet Psychiatry 2023 · Meta-Analysis, Systematic Review
- Intraoperative methadone administration and postoperative pain control: a systematic review and meta-analysis.
D'Souza RS, Gurrieri C, Johnson RL, et al. · Pain 2020 · Meta-Analysis, Systematic Review
- Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo L, Barrio G, Bravo MJ, et al. · BMJ 2017 · Meta-Analysis, Systematic Review
- Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis.
Ray LA, Meredith LR, Kiluk BD, et al. · JAMA Netw Open 2020 · Meta-Analysis, Research Support, N.I.H., Extramural
- Shifting Views on Cancer Pain Management: A Systematic Review and Network Meta-Analysis.
Imkamp MSV, Theunissen M, Viechtbauer W, et al. · J Pain Symptom Manage 2024 · Systematic Review, Network Meta-Analysis
- Buprenorphine Compared with Methadone in Pregnancy: A Systematic Review and Meta-Analysis.
Kinsella M, Halliday LOE, Shaw M, et al. · Subst Use Misuse 2022 · Meta-Analysis, Systematic Review
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.